{
  "id" : "extension_bci",
  "algorithm" : "eod_public",
  "version" : "3.3",
  "name" : "EOD Primary Tumor",
  "title" : "EOD Primary Tumor",
  "notes" : "**Note 1:** **The preferred histology terms listed below are from the 2024 WHO Classification of Tumours, Haematolymphoid tumours, 5th edition.**\n\n**Note 2:** **The following histologies can be localized (code 100), systemic (700) or unknown (999)** \n\n* 9740: Mast cell sarcoma (MCS)\n* 9749: Erdheim-Chester disease (ECD) (2021+ only)\n* 9755: Histiocytic sarcoma\n* 9756: Langerhans cell sarcoma (LCS) \n* 9757: Interdigitating dendritic cell sarcoma (IDCS) \n* 9758: Follicular dendritic cell sarcoma (FDCS) \n* 9759: Fibroblastic reticular cell tumor \n* 9766: Lymphomatoid granulomatosis, grade 3 (2021+ only)\n* 9930: Myeloid sarcoma \n* 9971: Polymorphic PTLD (2018-2020, 2025+) \n  * *Note:* 9971 is /1 and non-reportable (except for C700-C729, C751-C753) for 2021-2024, moved back to /3 for 1/1/2025+\n\n**Note 3:** **Lymph node involvement** \n* For histologies listed in **Note 1**, it is possible to have lymph node involvement; however, at this time, lymph node involvement for these histologies is not collected.\n\n**Note 4:** **The following histologies are systemic (code 700):**\n\n* 9591: Splenic B-cell lymphoma/leukemia, unclassifiable (except C441, C690, C695-C696)\n* 9724: Systemic EBV-positive T-cell lymphoma of childhood (SEBVTCL)\n* 9727: Blastic plasmacytoid dendritic cell neoplasm (BPDC)\n* 9741: Systemic mastocytosis with an associated hematological neoplasm (SM-AHN)\n* 9742: Mast cell leukemia (MCL)\n* 9750: ALK-positive histiocytosis\n* 9751: Langerhans cell histiocytosis (LCH), disseminated\n* 9762: Heavy chain diseases, NOS (HCD)\n* 9800: Leukemia, NOS\n* 9801: Acute undifferentiated leukemia\n* 9805: Acute leukemia of ambiguous lineage with other defined genetic alterations\n* 9806: Mixed-phenotype acute leukemia (MPAL) with *BCR::ABL1* fusion\n* 9807: Mixed-phenotype acute leukemia (MPAL) with *KMT2A-rearranged*\n* 9808: Mixed -phenotype acute leukemia, B/myeloid, NOS\n* 9809: Mixed-phenotype acute leukemia (MPAL), T/myeloid, NOS\n* 9811: B-lymphoblastic leukemia/lymphoma [B-ALL/LBL], NOS\n* 9812: B-lymphoblastic leukemia/lymphoma [B-ALL/LBL] with *BCR::ABL1 fusion*\n* 9813: B lymphoblastic leukemia/lymphoma [B-ALL/LBL] with *KMT2A rearrangement*\n* 9814: B-lymphoblastic leukemia/lymphoma [B-ALL/LBL] with *ETV6::RUNX1 fusion*\n* 9815: B-lymphoblastic leukemia/lymphoma with high hyperdiploidy (B-ALL/LBL with high hyperdiploidy)\n* 9816: B-lymphoblastic leukemia/lymphoma [B-ALL/LBL] with hypodiploidy (Hypodiploid B-ALL/LBL)\n* 9817: B-lymphoblastic leukemia/lymphoma [B-ALL/LBL] with *IGH::IL3 fusion*\n* 9818: B-lymphoblastic leukemia/lymphoma [B-ALL/LBL] with *TCF3::PBX1*\n* 9819: B-lymphoblastic leukemia/lymphoma [B-ALL/LBL] with *BCR::ABL1 like features* (BCR::ABL1-like B-ALL/LBL) (2021+ only)\n* 9820: Lymphoid leukemia, NOS\n* 9831: T-large granular lymphocytic leukemia (T-LGLL)\n* 9832: Prolymphocytic leukemia (PPL), NOS\n* 9833: Prolymphocytic leukemia, B-cell type (BLL) \n* 9834: T-cell prolymphocytic leukemia (T-PLL)\n* 9837: T-lymphoblastic leukemia/lymphoma (T-ALL/LBL) \n* 9840: Acute erythroid leukemia (AEL)\n* 9860: Myeloid leukemia, NOS\n* 9861: Acute myeloid leukemia (AML), NOS\n* 9863: Chronic myeloid leukemia (CML), NOS\n* 9865: Acute myeloid leukemia with *DEK::NUP214 fusion*\n* 9866: Acute promyelocytic leukemia with *PML::RARA* fusion (APL with *PML::RARA*)\n* 9867: Acute myelomonocytic leukemia, NOS (AMML)\n* 9869: Acute myeloid leukemia with *MECOM rearrangement*\n* 9870: Acute basophilic leukemia\n* 9871: Acute myeloid leukemia with *CBFB::MYH11 fusion*\n* 9872: Acute myeloid leukemia, minimal differentiation\n* 9873: Acute myeloid leukemia without maturation\n* 9874: Acute myeloid leukemia with maturation\n* 9875: Chronic myeloid leukemia (CML), *BCR::ABL1 positive*\n* 9876: Myelodysplastic/myeloproliferative neoplasm with neutrophilia (MDS/MPN-N)\n* 9877: Acute myeloid leukemia with mutated *NPM1* (2021+ only)\n* 9878: Acute myeloid leukemia with *CEBPA mutation* (2021+ only)\n* 9879: Acute myeloid leukemia with mutated *RUNX1* (2021+ only)\n* 9891: Acute monocytic leukemia\n* 9895: Myelodysplasia-related acute myeloid leukemia (AML-MR)\n* 9896: Acute myeloid leukemia with *RUNX1::RUNX1T1*\n* 9897: Acute myeloid leukemia with *KMT2a rearrangement*\n* 9898: Myeloid leukemia associated with Down Syndrome (ML-DS)\n* 9910: Acute megakaryoblastic leukemia (AMKL)\n* 9911: Acute myeloid leukemia (megakaryoblastic) with *RBMI5::MRTFA*\n* 9912: Acute myeloid leukemia with *BCR::ABL1 fusion* (2021+ only)\n* 9920 Therapy-related myeloid neoplasms\n* 9931: Acute panmyelosis with myelofibrosis (APMF)\n* 9940: Hairy cell leukemia (HCL)\n* 9945: Chronic myelomonocytic leukemia, NOS (CMML)\n* 9946: Juvenile myelomonocytic leukemia (JMML)\n* 9948: Aggressive NK-cell leukemia (ANKL)\n* 9950: Polycythemia vera (PV)\n* 9961: Primary myelofibrosis (PMF)\n* 9962: Essential thrombocythemia (ET)\n* 9963: Chronic neutrophilic leukemia (CNL)\n* 9964: Chronic eosinophilic leukemia (CEL)\n* 9965: Myeloid/lymphoid neoplasms with *PDGFRA* rearrangement\n* 9966: Myeloid/lymphoid neoplasm with *PDGFRB* rearrangement\n* 9967: Myeloid/lymphoid neoplasm with *FGFR1* rearrangement\n* 9968: Myeloid/lymphoid neoplasm with *JAK2* rearrangement (2021+ only)\n* 9975: Myelodysplastic/myeloproliferative neoplasm, NOS, unclassifiable (MPN/MDS-U)\n* 9980: Myelodysplastic neoplasm with low blasts and single-lineage dysplasia (MDS-LB-SLD)\n* 9982 Myelodysplastic /myeloproliferative neoplasm with low blasts and SF3B1 mutation\n* 9983: Myelodysplastic neoplasm with increased blasts (MDS-IB)\n* 9985: Myelodysplastic neoplasm with low blasts, NOS (MDS-LB)\n* 9986: Myelodysplastic neoplasm with low blasts and 5q deletion (MDS-5q)\n* 9989: Myelodysplastic neoplasm, NOS\n* 9991: Refractory neutropenia (2018-2020 only, see code 9980/3 for 2021+)\n* 9992: Refractory thrombocytopenia (2018-2020 only, see code 9980/3 for 2021+)\n* 9993: Myelodysplastic syndrome with ring sideroblasts and multilineage dysplasia (2021+)",
  "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) **Introduction to Hematologic Malignancies**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(6) Radich, J.P., Jaffe, E.S., Leonard, J.P., et al. **Leukemia**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017",
  "last_modified" : "2025-11-14T20:06:00.989Z",
  "definition" : [ {
    "key" : "eod_primary_tumor",
    "name" : "Code",
    "type" : "INPUT"
  }, {
    "key" : "description",
    "name" : "Description",
    "type" : "DESCRIPTION"
  }, {
    "key" : "ss2018_t",
    "name" : "SS2018 T",
    "type" : "ENDPOINT"
  } ],
  "rows" : [ [ "100", "Localized disease\n(Single/solitary/unifocal/isolated)\n\nSee Notes 1 and 2", "VALUE:L" ], [ "700", "Systemic disease\n\nSee Note 3", "VALUE:D" ], [ "999", "Unknown; extension not stated\nPrimary tumor cannot be assessed\nNot documented in medical record\n\nDeath Certificate Only", "VALUE:U" ] ]
}